China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer
GenSci holds exclusive Chinese rights to Camcevi, covering central precocious puberty, premenopausal breast cancer, and advanced prostate cancer.
Drug Development
Southern Research secures NIH funding for drug testing hub
FDA approves Asahi Kasei’s Hovilpri for refractory HSV
Perceptive, Nucleus partner to support radiopharmaceutical development
Bio-Techne opens GMP small molecule facility in Bristol, UK
Biohaven partners with Ono in $100m IgG degrader deal
FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
10x Genomics and Fred Hutch partner on cancer technologies
